Abstract
HIV-1 broadly neutralizing antibodies (bNAbs) are being explored as passively administered therapeutic and preventative agents. However, the extensively diversified HIV-1 envelope glycoproteins (Env) rapidly acquire mutations to evade individual bNAbs in monotherapy regimens. The use of a "single" agent to simultaneously target distinct Env epitopes is desirable to overcome viral diversity. Here, we report the use of tandem single-chain variable fragment (ScFv) domains of two bNAbs, specific for the CD4-binding site and V3 glycan patch, to form anti-HIV-1 bispecific ScFvs (Bi-ScFvs). The optimal Bi-ScFv crosslinks adjacent protomers within one HIV-1 Env spike and has greater neutralization breadth than its parental bNAbs. Furthermore, the combination of this Bi-ScFv with a third bNAb recognizing the Env membrane proximal external region (MPER) results in a trispecific bNAb, which has nearly pan-isolate neutralization breadth and high potency. Thus, multispecific antibodies combining functional moieties of bNAbs could achieve outstanding neutralization capacity with augmented avidity.
Publication types
-
Research Support, N.I.H., Intramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Neutralizing / chemistry
-
Antibodies, Neutralizing / immunology
-
Antibodies, Neutralizing / pharmacology
-
Antibodies, Neutralizing / therapeutic use
-
Antiviral Agents / chemistry
-
Antiviral Agents / immunology
-
Antiviral Agents / pharmacology*
-
Antiviral Agents / therapeutic use
-
Drug Combinations
-
Drug Design*
-
Epitopes / genetics
-
Epitopes / immunology
-
HIV Antibodies / chemistry
-
HIV Antibodies / immunology
-
HIV Antibodies / pharmacology*
-
HIV Antibodies / therapeutic use
-
HIV Infections / drug therapy*
-
HIV-1 / drug effects*
-
HIV-1 / genetics
-
HIV-1 / immunology
-
Humans
-
Microscopy, Electron
-
Mutation
-
Protein Subunits / immunology
-
Single-Chain Antibodies / chemistry
-
Single-Chain Antibodies / immunology
-
Single-Chain Antibodies / pharmacology
-
Single-Chain Antibodies / therapeutic use
-
env Gene Products, Human Immunodeficiency Virus / antagonists & inhibitors*
-
env Gene Products, Human Immunodeficiency Virus / genetics
-
env Gene Products, Human Immunodeficiency Virus / immunology
Substances
-
Antibodies, Neutralizing
-
Antiviral Agents
-
Drug Combinations
-
Epitopes
-
HIV Antibodies
-
Protein Subunits
-
Single-Chain Antibodies
-
env Gene Products, Human Immunodeficiency Virus